Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as REGN668: Injection Rate 1
REGN668: Rate 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN668: Injection Rate 1 | DRUG | Subjects will receive REGN668 via SC injection |
| REGN668: Injection Rate 2 | DRUG | Subjects will receive study drug via alternate delivery (if necessary) |
Inclusion Criteria: 1. Male or female subjects 18 to 55 years of age. 2. Body weight between 60 kg and 80 kg, body mass index between 20 and 30 kg/m2 inclusive. 3. NHV as evidenced by comprehensive clinical assessment (detailed medical history and complete physical examination). 4. Normal resting b...
REGN668: Rate 1 is an investigational small molecule developed by Regeneron Pharmaceuticals, Inc. (ticker REGN). It has been studied in a Phase 1 clinical trial in healthy adult volunteers, evaluating safety, tolerability, pharmacokinetics, and immunogenicity when administered subcutaneously. It is not an approved therapy and remains in clinical development.
REGN668: Rate 1 is developed by Regeneron Pharmaceuticals, Inc., which trades under the ticker REGN. Regeneron sponsored the Phase 1 study of the compound in healthy volunteers conducted in the United States.
REGN668: Rate 1 is in Phase 1 clinical development. Its single recorded trial, NCT01484600, was a Phase 1 study that has been completed. The drug is investigational and has not been approved for any indication.
REGN668: Rate 1 has been evaluated in one clinical trial, NCT01484600, titled a study of the safety, tolerability, pharmacokinetics, and immunogenicity of REGN668 administered subcutaneously to healthy volunteers. The Phase 1 trial enrolled 36 participants in the United States and is completed.
Yes, REGN668: Rate 1 is also known as REGN668: Injection Rate 1. Both names refer to the same Regeneron Pharmaceuticals compound studied in the Phase 1 trial NCT01484600 in healthy volunteers.
REGN668: Rate 1 has been studied in healthy adult volunteers rather than in a patient population. Its completed Phase 1 trial, NCT01484600, assessed safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous administration in 36 participants. No approved therapeutic use has been established.